[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"internal-piles-sclerotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:internal-piles-sclerotherapy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100659505","phase-4-evaluation-of-polidocanol-foam-sclerotherapy-in-symptomatic-internal-hemorrhoids-a-prospective-study-100659505",false,"NCT07866248","Evaluation of Polidocanol Foam Sclerotherapy in Symptomatic Internal Hemorrhoids: A Prospective Study","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Symptomatic internal hemorrhoidal disease.\n3. Goligher grade II or III hemorrhoids.\n4. Predominant hemorrhoidal bleeding (\\>or equal 2 episodes of rectal bleeding\u002F week in last 4 weeks) and\u002For prolapse.\n5. Persistent symptoms despite 4 to 6 weeks of conservative treatment (high fibers diet 25\u002F30 g\u002Fday, increase water intake, avoid straining, stool softening and topical treatment as anesthetics and corticosteroids containing preparations) .\n6. Suitable for outpatient Polidocanol foam sclerotherapy treatment.\n7. Willingness to comply with the study protocol.\n\nExclusion Criteria:\n\n1. Goligher grade IV hemorrhoids.\n2. Predominantly external hemorrhoidal disease.\n3. Acute thrombosed hemorrhoids.\n4. Active anorectal infection.\n5. Anal fissure or fistula responsible for presenting symptoms.\n6. Known colorectal malignancy.\n7. Active inflammatory bowel disease involving the anorectal region.\n8. Uncorrected bleeding disorder.\n9. Known hypersensitivity to polidocanol.\n10. Previous hemorrhoidal surgery substantially altering anorectal anatomy.\n11. Severe uncontrolled systemic illness preventing the procedure.\n12. Pregnancy where treatment is considered inappropriate according to institutional policy.\n13. Inability to provide informed consent.\n14. Inability to complete follow-up.\n\n    \\-","ALL","18 Years","80 Years",{"count":19,"type":20},130,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","To evaluate the efficacy, durability, safety, and clinical\u002Fendoscopic outcomes of standardized 3% polidocanol foam sclerotherapy in patients with symptomatic grade II-III internal hemorrhoids over a 12-month follow-up period.",[26,27],"Internal Piles Sclerotherapy","Internal Hemorrhoids","NOT_YET_RECRUITING","2026-10-04",{"date":31,"type":32},"2026-10-08","ACTUAL",{"date":34,"type":20},"2026-10-01",{"date":36,"type":20},"2028-09-01",{"name":38,"class":39},"Radwa Hussein Mohammed Hasanen","OTHER"]